Infection of Upper Respiratory Tract Caused by 2019-nCoV
Conditions
Keywords
2019-nCoV
Brief summary
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
Interventions
DRUGSA55 Injection
Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
Sponsors
Sinovac Life Sciences Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male or female aged ≥ 18 years on the day of enrollment; * On the day of enrollment, novel coronavirus nucleic acid test was positive and/or novel coronavirus antigen test was positive; * On the day of enrollment, it meets the criteria for mild or medium COVID-19 cases, and the time from the first COVID-19 infection related symptoms is within 72 hours; * Within 24 hours before enrollment, one or more of the following symptoms or signs must be present: a. fever, b. cough, c. sore throat, d. nasal congestion/runny nose, e. headache, f. muscle pain, g. shortness of breath/difficulty breathing, h. nausea, i. fatigue, j. vomiting, k. diarrhea; * Subjects (male and female of childbearing age) and their sexual partners voluntarily take effective contraceptive measures within 6 months after signing the informed consent form and administering the experimental drug, and do not have plans to donate sperm or eggs; * At rest, when inhaling air, the oxygen saturation is greater than 93%; * Subjects voluntarily participate in the experiment and sign an informed consent form before the start of the study.
Exclusion criteria
* Individuals who are known to be allergic to the investigational drug, any component in the preparation, or other similar drugs; * Individuals weighing less than 40 kg; * There are comorbidities that require surgery within one month, or comorbidities that are considered life-threatening within one month; * Before screening, he has received neutralizing antibody drugs from COVID-19, or received human immunoglobulin or convalescent plasma treatment from convalescent patients within 3 months, or received small molecule drugs from COVID-19 within 7 days; * Suspected or confirmed to have combined serious and active bacterial, fungal, viral or other infections (except for COVID-19 infection), such as acute systemic infection, the researcher believes that intervention measures may pose a risk; * Individuals who tested positive for influenza A/B virus antigens during screening; * Plan to become pregnant within 6 months, already pregnant, or breastfeeding; * Participated in clinical trials of other drugs or medical devices within 3 months prior to screening; * Having/having suffered from severe neurological disorders (epilepsy, convulsions, or seizures) or mental illness, or having a family history of mental illness; * Suffering from/having previously suffered from severe neurological diseases or other serious illnesses that the researcher has determined to be unsuitable for participation in the study (including but not limited to current systemic infections, uncontrolled autoimmune diseases, uncontrolled immunodeficiency diseases, history of myocardial infarction or heart disease, etc.); * Unable to cooperate with the follow-up of the study, or unable to guarantee the non use of concomitant drugs/vaccines/treatments prohibited by this protocol during the study period (see section 6.4.2); * The researcher believes that due to other reasons, it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients | from baseline to D3, D5, D7 | Changes of novel coronavirus (SARS-CoV-2) load from baseline to D3, D5, D7 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients (impact on virological indicators) | (1) D9, D11, D15 (2) After administration (3) D3, D5, D7, D9, D11, D15 | (1) Changes in SARS-CoV-2 virus load relative to baseline at different time points; (2) Time to achieve continuous negative conversion of SARS-CoV-2 nucleic acid; (3) The proportion of subjects who achieved continuous negative SARS-CoV-2 nucleic acid conversion at different time points |
| Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients (impact on clinical indicators) | an average of 1 year | Within 28 days after administration: the time of continuous disappearance of clinical symptoms and the time of continuous remission of clinical symptoms of 5, 7 and 11 COVID-19; The proportion of subjects who progress to severe/critically ill conditions; Hospitalization rate due to COVID-19; All cause mortality rate; Rescue treatment rate; Change of clinical symptom score of COVID-19 from baseline to different time points |
| Evaluate the safety of SA55 injection in mild or moderate COVID-19 patients | an average of 1 year | The incidence of adverse events; The incidence of serious adverse events |
| Evaluation of serum COVID-19 neutralizing activity at different time points | an average of 1 year | Serum pharmacokinetic parameters of SA55 after medication (peak time Tmax, peak concentration Cmax, area under the drug time curve AUC0-t, AUC0- ∞, elimination half-life t1/2, apparent clearance rate CL/F, apparent distribution volume Vd/F, etc.) |
| Evaluating the immunogenicity of SA55 injection | an average of 1 year | Serum anti drug antibody (ADA) levels at different time points |
| Evaluate the pharmacokinetic characteristics of SA55 injection in mild or moderate COVID-19 patients | an average of 1 year | Serum pharmacokinetic parameters of SA55 after medication (peak time Tmax, peak concentration Cmax, area under the drug time curve AUC0-t, AUC0- ∞, elimination half-life t1/2, apparent clearance rate CL/F, apparent distribution volume Vd/F, etc.) |
Countries
China
Contacts
Primary ContactGuang Ning, M.D.
Outcome results
None listed